Ana Aragón-González

As a post-doctoral researcher, Ana focuses on studying the cellular and molecular mechanisms of neurodegeneration and dementia.

Dr. Aragón employs CRISPR technology to deactivate target genes in human iPSC-derived dopaminergic neurons. As a post-doctoral researcher, she studies the cellular trafficking and aggregation of α-synuclein, aiming to identify modifiers that influence its turnover and aggregation. Her research involves a range of biochemical and microscopy techniques.

Her goal is that her work on the genetic and molecular features of Parkinson’s disease can ultimately benefit patients.

Before joining the University of Oxford, Dr. Aragón earned a BSc in Biochemistry and an MSc in Neuroscience from the University of Barcelona. She then carried out her doctoral research as a Marie Curie ERC fellow at the University of Sheffield, in collaboration with the University of Malaga, focusing on the dynamics of the Blood-Brain Barrier (BBB) in the context of Motor Neuron Disease. During her intership in the U.S., supported by Fulbright Spain, she also explored BBB alterations in Rett Syndrome.

Ana is also involved in mentoring programs and the Spanish Researchers Society in the UK SRUK/CERU, currently participating as a member of the annual symposium organising committee.